This article is for informational and educational purposes only and does not constitute medical advice. Livagen is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
Livagen is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Ala (KEDA) and a molecular weight of approximately 461 Da. It belongs to the peptide bioregulator class developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, originally derived from research on bovine liver tissue extracts. Unlike the majority of named bioregulators in this class — which share the Ala-Glu-Asp N-terminal tripeptide — Livagen begins with the basic residue lysine, giving it a distinct electrostatic and structural profile. The compound is described as a dual-action hepatic and immune bioregulator, with proposed activity in both liver parenchymal cells and lymphocytes, making it unusual within the Khavinson framework where most peptides are proposed to target a single tissue type. Proposed mechanisms include hepatic gene expression modulation and chromatin decondensation activity in liver and immune cells. As with other members of this compound class, the published evidence base is largely confined to the originating research group, independent replication by external laboratories has not been widely reported, and no regulatory authority has approved Livagen for any clinical indication.
1. Background
1.1 The Peptide Bioregulator Concept
Livagen belongs to the Khavinson peptide bioregulator class — a series of short synthetic peptides proposed to regulate gene expression in a tissue-specific manner by interacting with promoter regions of DNA. The theoretical framework, developed beginning in the Soviet Union in the 1970s and continuing through the post-Soviet Russian scientific program, holds that short peptides derived from organ extracts carry sequence-specific information that modulates transcription in the corresponding target tissue. For a broader review of the bioregulator class and its methodological context, see the companion articles on Epitalon (AEDG) and Pinealon (EDR).
Livagen was developed as a derivative of a peptide fraction isolated from bovine liver tissue. Among the named Khavinson bioregulators, it occupies a structurally distinctive position: while Epitalon (AEDG), Cardiogen (AEDR), Bronchogen (AEDL), and Cortagen (AEDP) all share the Ala-Glu-Asp N-terminal tripeptide, Livagen’s sequence begins with lysine (Lys, K) — a basic amino acid with a long aliphatic side chain and a positively charged ε-amine group at physiological pH. This places Livagen outside the AED- structural subfamily and gives it a different N-terminal charge and hydrogen-bonding geometry from the majority of studied Khavinson bioregulators.
1.2 Hepatic Biology and the Case for Liver Bioregulation
The liver is the body’s primary metabolic organ, performing functions that include carbohydrate, lipid, and protein metabolism; synthesis of plasma proteins (albumin, clotting factors, complement components); detoxification and biotransformation of endogenous and exogenous compounds; and bile production. Hepatocytes — the parenchymal cells of the liver — account for the majority of liver mass and carry out most of these metabolic functions through gene expression programs that are extensively regulated by transcription factors, hormonal signals, and nutritional state.
Unlike the cardiac or cortical neurons targeted by other bioregulators in this class, the liver possesses a well-characterized capacity for regeneration. Following partial hepatectomy or injury, residual hepatocytes re-enter the cell cycle and proliferate to restore liver mass, a process that can restore near-complete organ function [3]. This regenerative capacity means that age-associated decline in liver function is more likely to reflect changes in gene expression, metabolic efficiency, and stress response in surviving hepatocytes than irreversible cell loss of the kind seen in post-mitotic tissues. The Khavinson group’s rationale for a hepatic bioregulator was grounded in the hypothesis that KEDA might restore or support the gene expression programs associated with healthy liver function in aging hepatocytes.
Livagen’s proposed activity extends beyond liver parenchyma to lymphocytes and other immune cells. This dual targeting reflects the liver’s recognized role as a major immunological organ: the liver’s sinusoidal architecture accommodates Kupffer cells (liver-resident macrophages), natural killer cells, and other lymphocyte populations; it is a primary site of complement synthesis and acute-phase protein production; and it is subject to extensive immune surveillance at the interface of portal and systemic circulation. The mechanistic basis for a single short peptide simultaneously targeting hepatocyte and lymphocyte gene expression within the Khavinson tissue-specificity framework, however, has not been formally resolved.
2. Molecular Structure
| Property | Value |
|---|---|
| Full name | Livagen |
| Sequence (single-letter) | KEDA |
| Sequence (full names) | Lys-Glu-Asp-Ala |
| Molecular weight | ~461 Da |
| Molecular formula | C ₁₈H ₃₁N ₅O ₉ |
| Peptide length | 4 amino acids (tetrapeptide) |
| Net charge (physiological pH) | −1 (Lys +1; Glu −1; Asp −1; Ala uncharged) |
| N-terminal residue note | Lys at position 1 is a basic amino acid with an ε-amine group (pKa ~10.5); this distinguishes Livagen from all AED- series bioregulators, which begin with neutral Ala |
| Origin | Synthetic; sequence derived from bovine liver tissue extract research |
| Proposed primary target | Hepatocyte gene promoter regions and lymphocyte chromatin (proposed dual-tissue targeting) |
| Structural subfamily | Not part of the AED- series; compare Epitalon (AEDG), Cardiogen (AEDR), Bronchogen (AEDL), Cortagen (AEDP) |
The lysine residue at position 1 is the defining structural feature that sets Livagen apart from the AED- bioregulator family. Lysine carries a four-carbon aliphatic chain terminating in a primary ε-amine group that is fully protonated (positively charged) at physiological pH. This basic N-terminus creates a dipolar charge distribution across the KEDA tetrapeptide — positive at the N-terminal Lys, negative at the Glu-Asp positions 2 and 3 — that differs substantially from the near-uniform negative character of the AED- series. Within the Khavinson framework, this distinct charge geometry has been proposed as relevant to hepatocyte-specific promoter recognition, though the structural basis for liver versus cardiac or cortical selectivity among these short peptides has not been independently validated by biophysical experiment.
3. Proposed Mechanisms of Action
4. Key Research Findings
4.1 In Vitro Hepatic Cell Studies
The primary in vitro evidence base for Livagen centers on studies using hepatic cell preparations. The Khavinson group has reported that KEDA treatment in these systems is associated with changes in markers of hepatocyte gene expression, chromatin condensation state, and cell viability under stress conditions [1]. These in vitro observations are presented within the theoretical framework of the Khavinson bioregulator class, and the proposed chromatin decondensation and hepatoprotective effects form the primary mechanistic basis for the compound’s research interest.
Contemporary hepatology research employs experimental systems — including primary human hepatocyte preparations, induced pluripotent stem cell (iPSC)-derived hepatocytes, liver organoids, and single-cell RNA sequencing — that permit far more granular investigation of gene expression and chromatin changes than were available when the Khavinson bioregulator studies were conducted. Replication using these methods by independent laboratories has not been reported.
4.2 Lymphocyte and Immune Cell Studies
A distinctive feature of the Livagen literature is the reporting of immune cell effects alongside hepatic effects. The Khavinson group has reported that KEDA treatment of lymphocyte preparations is associated with changes in chromatin condensation state and immune activation markers, paralleling the hepatic chromatin observations [1]. These immune cell findings constitute the basis for the compound’s “dual-action” characterization. The same limitations that apply to the hepatic data — single-group origin, absence of independent replication, and methodological opacity in available publications — apply equally to the lymphocyte evidence.
Schematic representation of evidence depth at each research stage. Bar lengths are qualitative, not derived from a numerical index. Independent replication in each category is absent or minimal as of the review date.
4.3 Published Human Data
Published human data relevant to Livagen are very limited. No peer-reviewed, randomized, placebo-controlled trial of Livagen in human subjects has been identified as of the review date. The Khavinson group has reported observational data encompassing multiple bioregulator peptides in clinical populations, but controlled trials with Livagen as the primary intervention and hepatic or immune endpoints as pre-registered primary outcomes have not been identified [2].
The absence of controlled human trial data means that no assessment of safety, tolerability, hepatic bioavailability, pharmacokinetics, or liver or immune efficacy in human subjects can be drawn from the published evidence. Demonstrating hepatic or immunological effects in humans would require adequately powered, double-blind randomized trials with validated hepatic function endpoints and pre-registered immune biomarkers — a methodological standard that has not been applied to Livagen.
5. Evidence Status
| Proposed Effect | Current Status | Evidence Level |
|---|---|---|
| Hepatic gene expression modulation | Reported in vitro by Khavinson group; no independent replication published | Limited |
| Chromatin decondensation (hepatocytes) | Reported by Khavinson group; no independent epigenomics validation | Limited |
| Chromatin decondensation (lymphocytes) | Reported by Khavinson group; no independent validation | Limited |
| Hepatoprotective activity (in vitro) | In vitro observations from originating group; specific targets not characterized | Limited |
| Immune cell activation modulation | Lymphocyte data from Khavinson group; single group; not independently replicated | Limited |
| Human hepatic or immune outcomes | No controlled trials identified; no RCT data | Not Established |
| Sequence-specific promoter binding (KEDA) | Computational modeling only; no independent structural validation | Limited |
What We Still Don’t Know
- Whether hepatocyte chromatin and gene expression effects are reproducible by independent investigators: All published observations of Livagen’s effects on chromatin condensation and hepatic gene expression originate from the Khavinson group. Replication using contemporary tools — including ATAC-seq for chromatin accessibility, single-nucleus RNA sequencing, and human iPSC-derived hepatocyte models — by independent laboratories is necessary to validate these claims.
- How a single tetrapeptide targets two distinct cell types: The Khavinson bioregulator hypothesis is grounded in tissue-specific DNA interaction derived from organ-specific peptide origin. Livagen’s proposed dual targeting of hepatocytes and lymphocytes is mechanistically inconsistent with strict tissue specificity. Whether the compound acts through a common chromatin mechanism operative in both cell types, through distinct mechanisms in each, or through indirect hepatic-immune crosstalk has not been investigated.
- The pharmacokinetic profile following systemic administration: The plasma half-life, hepatic extraction fraction, and intracellular bioavailability of KEDA in liver parenchyma have not been characterized in published studies. Unlike a CNS-targeted peptide facing the blood-brain barrier, hepatic delivery is pharmacokinetically less obstructed — the liver receives both portal venous and arterial blood — but proteolytic degradation by serum and hepatic peptidases would still limit bioavailability of an unmodified tetrapeptide.
- The structural basis for KEDA hepatic selectivity: Within the Khavinson framework, KEDA’s basic N-terminal lysine is proposed to confer hepatic tissue specificity distinct from the AED- series. The electrostatic difference between KEDA and AEDG, AEDR, AEDL, or AEDP at physiological pH is real and structurally significant, but whether it translates to differential promoter-binding selectivity in hepatocytes versus other cell types has not been demonstrated in independent biophysical or genomic experiments.
- Whether chromatin decondensation activity translates to sustained transcriptional changes: Chromatin accessibility changes do not automatically translate to persistent alterations in gene expression output. The downstream transcriptomic consequences of the reported chromatin decondensation — which genes are upregulated or downregulated, in what cell populations, and for how long — have not been characterized by comprehensive RNA-seq or proteomics studies.
6. Limitations of Current Research
References
- Khavinson VKh, Malinin VV. “Gerontological Aspects of Genome Peptide Regulation.” Basel: Karger; 2005. Monograph covering the peptide bioregulator class including hepatic tissue bioregulator research, in vitro hepatocyte and lymphocyte data, and chromatin activity observations.
- Anisimov VN, Khavinson VK. “Peptide bioregulation of aging: results and prospects.” Biogerontology. 2010;11(2):139–149. doi:10.1007/s10522-009-9249-8
- Taub R. “Liver regeneration: from myth to mechanism.” Nature Reviews Molecular Cell Biology. 2004;5(10):836–847. doi:10.1038/nrm1489 [Background reference on hepatocyte proliferative capacity and liver regeneration biology relevant to the tissue context discussion in this article.]